Skip to main content

Eluxadoline News

FDA Medwatch Alert: Viberzi (eluxadoline): Drug Safety Communication - Increased Risk of Serious Pancreatitis In Patients Without A Gallbladder

ISSUE: FDA is warning that Viberzi (eluxadoline), a medicine used to treat irritable bowel syndrome with diarrhea (IBS-D), should not be used in patients who do not have a gallbladder. An FDA review...

FDA Approves Viberzi (eluxadoline) for Irritable Bowel Syndrome with Diarrhea (IBS-D) in Adults

DUBLIN, May 27, 2015 /PRNewswire/ – Actavis plc (NYSE: ACT) announced today that Viberzi (eluxadoline) was approved by the Food and Drug Administration (FDA) as a twice-daily, oral treatment for...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

Diarrhea, Irritable Bowel Syndrome

Eluxadoline patient information at Drugs.com